Trabectedin: Novel Insights in the Treatment of Advanced Sarcoma

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2014 Apr 24

PMID 24756367

Citations 1

Authors

Jay Patrick Lopez

Csaba Gajdos

Anthony Elias

Affiliations

Soon will be listed here.

Abstract

Soft tissue sarcomas are a heterogenous group of malignancies with relatively high mortality rates. The outlook for these patients has been poor, with only a few drugs showing measurable activity. Trabectedin is a new alkylating agent with significant activity in sarcomas, but particularly in liposarcomas and leiomyosarcomas, both as a single agent or in combination with other drugs. Phase I and II studies of trabectedin have shown measurable benefit. Currently there are several Phase III trials which have completed accrual to better study its use as a single agent or in combination therapy, although outcomes have not yet been reported. Trabectedin (Yondelis) is approved for the treatment of sarcomas by the EMEA, but is not yet approved by the FDA, pending the results of the currently maturing phase III trials.

Citing Articles

Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy.

Cotechini T, Atallah A, Grossman A Cells. 2021; 10(4).

PMID: 33924237 PMC: 8074766. DOI: 10.3390/cells10040960.

References

Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J . In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998; 9(9):981-7. DOI: 10.1023/A:1008224322396. View

Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E . Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001; 19(5):1248-55. DOI: 10.1200/JCO.2001.19.5.1248. View

Rosenberg S, Tepper J, Glatstein E, Costa J, Young R, Baker A . Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer. 1983; 52(3):424-34. DOI: 10.1002/1097-0142(19830801)52:3<424::aid-cncr2820520307>3.0.co;2-8. View

Garcia-Carbonero R, Supko J, Manola J, Seiden M, Harmon D, Ryan D . Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004; 22(8):1480-90. DOI: 10.1200/JCO.2004.02.098. View

Erba E, Bergamaschi D, BASSANO L, Damia G, Ronzoni S, Faircloth G . Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001; 37(1):97-105. DOI: 10.1016/s0959-8049(00)00357-9. View

Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R . Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995; 13(7):1537-45. DOI: 10.1200/JCO.1995.13.7.1537. View

Edmonson J, Marks R, Buckner J, Mahoney M . Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest. 2002; 20(5-6):605-12. DOI: 10.1081/cnv-120002485. View

Patel S, Gandhi V, Jenkins J, Papadopolous N, Burgess M, Plager C . Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19(15):3483-9. DOI: 10.1200/JCO.2001.19.15.3483. View

Martinez E, Corey E, Owa T . Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol. 2002; 8(12):1151-60. DOI: 10.1016/s1074-5521(01)00082-5. View

10.

Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P . Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs. 2009; 21(1):113-9. DOI: 10.1097/CAD.0b013e328333057b. View

11.

Le Cesne A, Blay J, Judson I, van Oosterom A, Verweij J, Radford J . Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005; 23(3):576-84. DOI: 10.1200/JCO.2005.01.180. View

12.

Garcia-Rocha M, Avila J . Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer. 1996; 73(8):875-83. PMC: 2075815. DOI: 10.1038/bjc.1996.176. View

13.

Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A . Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma.... Oncologist. 2012; 17(9):1213-20. PMC: 3448415. DOI: 10.1634/theoncologist.2011-0467. View

14.

Chu Q, Mita A, Forouzesh B, Tolcher A, Schwartz G, Nieto A . Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010; 16(9):2656-65. DOI: 10.1158/1078-0432.CCR-10-0062. View

15.

Sessa C, Perotti A, Noberasco C, de Braud F, Gallerani E, Cresta S . Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2008; 45(7):1153-1161. DOI: 10.1016/j.ejca.2008.11.019. View

16.

Tanabe K, Pollock R, Ellis L, Murphy A, Sherman N, Romsdahl M . Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer. 1994; 73(6):1652-9. DOI: 10.1002/1097-0142(19940315)73:6<1652::aid-cncr2820730617>3.0.co;2-x. View

17.

Yang J, Chang A, Baker A, Sindelar W, DANFORTH D, Topalian S . Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16(1):197-203. DOI: 10.1200/JCO.1998.16.1.197. View

18.

Schoenfeld D, Rosenbaum C, Horton J, Wolter J, FALKSON G, DeConti R . A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982; 50(12):2757-62. DOI: 10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j. View

19.

McGee L, Indelicato D, Dagan R, Morris C, Knapik J, Reith J . Long-term results following postoperative radiotherapy for soft tissue sarcomas of the extremity. Int J Radiat Oncol Biol Phys. 2012; 84(4):1003-9. DOI: 10.1016/j.ijrobp.2012.01.074. View

20.

Fayette J, Coquard I, Alberti L, Ranchere D, Boyle H, Blay J . ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist. 2005; 10(10):827-32. DOI: 10.1634/theoncologist.10-10-827. View